Total Payments
$227,410
2024 Payments
$173,027
Companies
12
Transactions
191
Medicare Patients
11,172
Medicare Billing
$10.7M
Payment Breakdown by Category
Other$150,319 (66.1%)
Consulting$39,418 (17.3%)
Travel$25,045 (11.0%)
Research$6,575 (2.9%)
Food & Beverage$6,053 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,533 | 38 | 59.6% |
| Consulting Fee | $39,418 | 20 | 17.3% |
| Travel and Lodging | $25,045 | 27 | 11.0% |
| Honoraria | $14,786 | 6 | 6.5% |
| Unspecified | $6,575 | 2 | 2.9% |
| Food and Beverage | $6,053 | 98 | 2.7% |
Payments by Type
General
$220,835
189 transactions
Research
$6,575
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | $68,969 | 44 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $64,371 | 53 | $0 (2024) |
| Astellas Pharma US Inc | $58,061 | 38 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $14,503 | 9 | $0 (2024) |
| Genentech USA, Inc. | $6,991 | 15 | $0 (2024) |
| Coherus Biosciences Inc. | $6,305 | 5 | $0 (2023) |
| Ocular Therapeutix, Inc. | $6,300 | 14 | $0 (2024) |
| Alimera Sciences, Inc. | $1,410 | 6 | $0 (2024) |
| Heidelberg Engineering, Inc. | $350.00 | 1 | $0 (2024) |
| Genentech, Inc. | $62.70 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $173,027 | 126 | Apellis Pharmaceuticals, Inc. ($54,450) |
| 2023 | $52,534 | 52 | Regeneron Healthcare Solutions, Inc. ($18,454) |
| 2022 | $1,595 | 8 | Alimera Sciences, Inc. ($1,200) |
| 2021 | $116.06 | 3 | Regeneron Healthcare Solutions, Inc. ($85.27) |
| 2019 | $137.17 | 2 | Regeneron Healthcare Solutions, Inc. ($137.17) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $7,560.00 | General |
| Category: Ophthalmology | ||||||
| 12/16/2024 | Apellis Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $4,536.00 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,820.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Ophthalmology | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,434.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $1,419.94 | General |
| Category: Ophthalmology | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $121.13 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $1,507.46 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,434.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $125.02 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $27.59 | General |
| Category: Ophthalmology | ||||||
| 12/02/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $1,100.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $113.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/25/2024 | Ocular Therapeutix, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 11/23/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $29.31 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 11/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Ophthalmology | ||||||
| 11/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $1,374.44 | General |
| Category: Ophthalmology | ||||||
| 11/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Ophthalmology | ||||||
| 11/18/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $62.99 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 11/15/2024 | Ocular Therapeutix, Inc. | — | Travel and Lodging | In-kind items and services | $1,052.72 | General |
| 11/15/2024 | Ocular Therapeutix, Inc. | — | Travel and Lodging | In-kind items and services | $915.86 | General |
| 11/15/2024 | Ocular Therapeutix, Inc. | — | Food and Beverage | In-kind items and services | $37.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $6,575 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 3,290 | 94,565 | $11.7M | $4.3M |
| 2022 | 16 | 3,015 | 24,536 | $6.7M | $2.6M |
| 2021 | 15 | 2,483 | 9,474 | $5.3M | $2.1M |
| 2020 | 15 | 2,384 | 8,579 | $4.7M | $1.8M |
Total Patients
11,172
Total Services
137,154
Medicare Billing
$10.7M
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 276 | 83,052 | $4.3M | $2.4M | 55.2% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 190 | 1,662 | $2.0M | $1.1M | 56.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 611 | 2,400 | $3.4M | $221,310 | 6.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 628 | 2,293 | $710,644 | $214,485 | 30.2% |
| J3490 | Unclassified drugs | Office | 2023 | 24 | 54 | $182,894 | $102,135 | 55.8% |
| 92134 | Imaging of retina | Office | 2023 | 767 | 2,898 | $456,571 | $85,890 | 18.8% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 16 | 480 | $99,840 | $57,773 | 57.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 16 | 250 | $104,000 | $45,931 | 44.2% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 158 | 590 | $58,343 | $33,157 | 56.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 252 | 476 | $102,413 | $27,462 | 26.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 72 | 72 | $32,618 | $8,568 | 26.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 43 | 43 | $15,169 | $3,983 | 26.3% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 11 | 15 | $105,324 | $3,792 | 3.6% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 160 | 204 | $23,770 | $1,910 | 8.0% |
| 92250 | Photography of the retina | Office | 2023 | 21 | 25 | $5,908 | $674.37 | 11.4% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 16 | 18 | $18,594 | $540.29 | 2.9% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 13 | 13 | $1,455 | $167.58 | 11.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 16 | 20 | $169.00 | $15.25 | 9.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 232 | 2,301 | $2.6M | $1.6M | 63.9% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 122 | 14,700 | $763,224 | $438,481 | 57.5% |
| 67028 | Injection of drug into eye | Office | 2022 | 454 | 1,783 | $2.3M | $160,897 | 7.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 467 | 1,605 | $438,492 | $150,648 | 34.4% |
| 92134 | Imaging of retina | Office | 2022 | 629 | 2,230 | $262,094 | $66,788 | 25.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 240 | 725 | $67,352 | $39,417 | 58.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 248 | 405 | $74,864 | $23,758 | 31.7% |
About Dr. Deepak Sambhara, M.D
Dr. Deepak Sambhara, M.D is a Ophthalmology healthcare provider based in Wausau, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/06/2014. The National Provider Identifier (NPI) number assigned to this provider is 1083024574.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deepak Sambhara, M.D has received a total of $227,410 in payments from pharmaceutical and medical device companies, with $173,027 received in 2024. These payments were reported across 191 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($135,533).
As a Medicare-enrolled provider, Sambhara has provided services to 11,172 Medicare beneficiaries, totaling 137,154 services with total Medicare billing of $10.7M. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Wausau, WI
- Active Since 05/06/2014
- Last Updated 10/07/2020
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1083024574
Products in Payments
- EYLEA HD (Biological) $76,356
- Syfovre (Drug) $62,933
- Izervay (Drug) $57,911
- Cimerli (Biological) $6,305
- Vabysmo (Drug) $4,031
- Susvimo (Drug) $2,820
- EYLEA (Biological) $2,517
- ILUVIEN (Drug) $1,243
- DEXTENZA (Drug) $536.44
- Spectralis (Device) $350.00
- VABYSMO (Drug) $168.61
- YUTIQ (Drug) $167.03
- XIPERE (Drug) $48.82
- OZURDEX (Drug) $38.03
- SUSVIMO (Drug) $34.80
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Wausau
Susan Ksiazek, Md, MD
Ophthalmology — Payments: $5,883
Ophthalmology $5,883
Dr. John Flatter, M.d, M.D
Ophthalmology — Payments: $4,473
Ophthalmology $4,473
Maxwell Wingelaar, Md, MD
Ophthalmology — Payments: $1,969
Ophthalmology $1,969
Dr. Mathew Aschbrenner, Md, MD
Ophthalmology — Payments: $804.73
Ophthalmology $804.73
Dr. Thaddeus Krolicki, M.d, M.D
Ophthalmology — Payments: $710.82
Ophthalmology $710.82
Dr. Christopher Kucharski, M.d, M.D
Ophthalmology — Payments: $576.95
Ophthalmology $576.95